IRIC discoveries have spurred major advances in understanding the development of cancer and opened the way to the creation of new, more targeted therapeutic solutions. Its publications are a reflection of these accomplishments. They also demonstrate the Institute’s drive and productivity.
Drug combinations: a strategy to extend the life of antibiotics in the 21st century.Nat. Rev. Microbiol. 2019-03-01;17(3):141-155.
GLI1-inducible glucuronidation targets a broad spectrum of drugs.ACS Chem. Biol. 2019-02-14.
ERK2 regulates epithelial-to-mesenchymal plasticity through DOCK10-dependent Rac1/FoxO1 activation.Proc. Natl. Acad. Sci. U.S.A. 2019-02-06.
Role of SUMOylation in differential ERα transcriptional repression by tamoxifen and fulvestrant in breast cancer cells.Oncogene 2019-02-01;38(7):1019-1037.
Overcoming Drug Resistance through the Development of Selective Inhibitors of UDP-Glucuronosyltransferase Enzymes.J. Mol. Biol. 2019-01-18;431(2):258-272.
Biochemical and Structural Insights into the eukaryotic translation initiation factor eIF4E.Curr. Protein Pept. Sci. 2019-01-10.
The BioGRID interaction database: 2019 update.Nucleic Acids Res. 2019-01-08;47(D1):D529-D541.